Search Results
Dec 22, 2025, 05:07 ET AusperBio Completes Patient Enrollment in Phase III AUSHINE Study of AHB-137 for Chronic Hepatitis B
profile of AHB-137. The encouraging clinical efficacy observed to date, including a functional cure rate of approximately 30% recently presented at the HEP-DART 2025 conference, reinforces our confidence in the triple-mechanistic activities of AHB-137 and its potential to deliver functional cure for CHB
More news about: AusperBio Therapeutics Inc.
Dec 18, 2025, 13:30 ET MoEngage nhận thêm 180 triệu đô la trong vòng gọi vốn Series F, hoàn tất sự kiện tạo tính thanh khoản cho nhân viên và nhà đầu tư
tin cậy khác biệt với các chiến dịch tiếp thị. Trong khi đó, các tính năng Phân tích Sản phẩm nâng cao trong MoEngage Analytics giúp tạo cầu nối thu hẹp khoảng cách giữa hiểu biết và hành động. Bằng cách hợp nhất dữ liệu về hành vi với tương tác tức thời, MoEngage giúp các chuyên gia quản lý sản phẩm
More news about: MoEngage
Dec 12, 2025, 09:18 ET AusperBio Announces AHB-137 Monotherapy Achieved 30% Functional Cure Rate in HBe-negative CHB Patients on Stable Nucleos(t)ide Analogue (NA) Therapy
(AB-10-8002) of AHB-137, the company's lead investigational HBV therapeutic product. Results were presented in an oral session at HEP-DART 2025 conference (December 7–11, Honolulu, USA).
More news about: AusperBio Therapeutics Inc.
Dec 08, 2025, 08:30 ET Galmed Announces Acceptance of a Late-Breaking Abstract to be Presented at HEP-DART 2025 Meeting
stakeholders" said Allen Baharaff, CEO of Galmed Pharmaceuticals.About HEP-DARTHEP-DART started in 1995 as the "FIRST International Conference on Therapies for Viral Hepatitis." Since its inception in 1995, HEP-DART has provided a cutting-edge platform for tackling challenges in drug development
More news about: Galmed Pharmaceuticals Ltd.
Dec 06, 2025, 14:00 ET Hep B Free - Calls for Continued Universal Hepatitis B Birth-Dose Vaccination Despite Federal Advisory Shift
Dec. 6, 2025 /PRNewswire/ -- Hep B Free (Formerly SF Hep B Free - Bay Area) urges hospitals, clinicians, and public-health agencies to continue the universal newborn hepatitis B (Hep B) birth-dose vaccine protocol in light of the December 5 federal advisory
More news about: Hep B Free
Nov 12, 2025, 01:00 ET Millennials at highest risk of missing crucial cervical cancer screenings, finds survey commissioned by Roche
interventions that address the barriers millennials face. Commenting on the results, Professor Daniel Kelly OBE, Cardiff University, and Co-Chair of the HPV and Hep B Action Network at the European Cancer Organisation said: "Healthcare systems must evolve to meet women where and how they live offering flexible, person-centred
More news about: Roche
Nov 12, 2025, 01:00 ET Millennials at highest risk of missing crucial cervical cancer screenings, finds survey commissioned by Roche
interventions that address the barriers millennials face. Commenting on the results, Professor Daniel Kelly OBE, Cardiff University, and Co-Chair of the HPV and Hep B Action Network at the European Cancer Organisation said: "Healthcare systems must evolve to meet women where and how they live offering flexible, person-centred
More news about: Roche
Oct 20, 2025, 11:30 ET Human Epilepsy Project Provides Uplifting News for Patients with Focal Treatment-Resistant Epilepsy
/PRNewswire/ -- The Epilepsy Foundation of America along with New York University announced today the results of the Human Epilepsy Project 2 (also known as HEP2), a biomarker research study. This study monitored 146 people with focal treatment-resistant epilepsy (FTRE) for up to three years to measure changes
More news about: Epilepsy Foundation
Oct 13, 2025, 12:02 ET Health Enterprise Partners Announces Second Annual RISE Above Award Winner
2025 /PRNewswire/ -- Health Enterprise Partners ("HEP") today announced Patrick McGrath, PhD, Chief Clinical Officer of NOCD, as the recipient of its second annual RISE Above Award. The award was established in honor of Steve Filchock, who joined HEP 14 years ago and provides the firm with technical
More news about: Health Enterprise Partners